Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PainReform Ltd. stock logo
PRFX
PainReform
$1.01
+12.2%		$1.06
$0.85
▼
$7.95
$780K1.0585,908 shs6.06 million shs
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$0.55
-4.4%		$0.66
$0.54
▼
$2.79
$3.50M4.965.60 million shs215,328 shs
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
$0.92
+9.2%		$1.20
$0.84
▼
$8.62
$2.98M2.5455,367 shs125,009 shs
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
$1.78
-5.3%		$2.12
$1.73
▼
$7.05
$3.42M0.75194,520 shs48,490 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PainReform Ltd. stock logo
PRFX
PainReform
+12.22%+6.28%+4.10%-38.79%-85.36%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-4.36%-21.43%-5.98%-32.42%-64.15%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
+9.17%-1.72%-14.44%-43.66%-83.96%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
-5.32%-17.59%-13.59%-14.83%-58.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PainReform Ltd. stock logo
PRFX
PainReform
$1.01
+12.2%		$1.06
$0.85
▼
$7.95
$780K1.0585,908 shs6.06 million shs
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$0.55
-4.4%		$0.66
$0.54
▼
$2.79
$3.50M4.965.60 million shs215,328 shs
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
$0.92
+9.2%		$1.20
$0.84
▼
$8.62
$2.98M2.5455,367 shs125,009 shs
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
$1.78
-5.3%		$2.12
$1.73
▼
$7.05
$3.42M0.75194,520 shs48,490 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PainReform Ltd. stock logo
PRFX
PainReform
+12.22%+6.28%+4.10%-38.79%-85.36%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-4.36%-21.43%-5.98%-32.42%-64.15%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
+9.17%-1.72%-14.44%-43.66%-83.96%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
-5.32%-17.59%-13.59%-14.83%-58.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PainReform Ltd. stock logo
PRFX
PainReform
1.00
SellN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
1.00
SellN/AN/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
2.00
Hold$13.851,398.92% Upside
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest PRFX, RDHL, SXTP, and XRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/3/2026
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
PainReform Ltd. stock logo
PRFX
PainReform
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PainReform Ltd. stock logo
PRFX
PainReform
$20K43.94N/AN/A$23.07 per share0.04
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$290K11.53N/AN/A$0.83 per share0.66
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
$1.41M2.31N/AN/A($5.85) per share-0.16
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/AN/AN/AN/A$1.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PainReform Ltd. stock logo
PRFX
PainReform
-$5.02M-$736.66N/AN/AN/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-$430K$900.000.00N/AN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
-$7.36M-$4.82N/AN/AN/A-650.21%N/A-136.81%11/12/2026 (Estimated)
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
-$2.66M-$2.73N/AN/AN/AN/A-137.85%-108.16%11/12/2026 (Estimated)

Latest PRFX, RDHL, SXTP, and XRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/3/2026Q2 2026
PainReform Ltd. stock logo
PRFX
PainReform
N/A-$1.13N/A-$1.1250N/A$0.01 million
8/15/2026Q2 2026
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A-$1.05N/A-$1.05N/AN/A
8/14/2026Q2 2026
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
-$0.74-$0.90-$0.16-$0.90$0.21 million$0.21 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PainReform Ltd. stock logo
PRFX
PainReform
N/A
5.07
1.78
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/A
0.34
0.34
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
N/A
2.32
1.78
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A
3.58
3.58

Institutional Ownership

CompanyInstitutional Ownership
PainReform Ltd. stock logo
PRFX
PainReform
37.28%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
7.20%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
7.96%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
0.23%

Insider Ownership

CompanyInsider Ownership
PainReform Ltd. stock logo
PRFX
PainReform
34.40%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
6.81%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
1.68%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
PainReform Ltd. stock logo
PRFX
PainReform
4870,000570,000Not Optionable
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
2106.08 million5.67 millionNo Data
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
33.52 million3.46 millionNot Optionable
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A1.82 million1.69 millionNot Optionable

Recent News About These Companies

XORTX Therapeutics (NASDAQ:XRTX) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?
September 15 at 2:03 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31023674
XORTX Begins Clinical, Commercial Manufacturing Of XORLO For Gout Program; Shares Surge To 31%
September 11, 2026  |  rttnews.comhttps://www.rttnews.com/3690223/xortx-begins-clinical-commercial-manufacturing-of-xorlo-for-gout-program-shares-surge-to-31.aspx
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
September 10, 2026  |  financialpost.comF
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359975/0/en/xortx-announces-initiation-of-clinical-and-commercial-manufacturing-of-xorlo.html
XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile
September 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xortx-re-engages-ir-firm-after-tsxv-delisting-to-bolster-nasdaq-focused-profile?utm_source=marketbeat.com&utm_medium=referral
XORTX Re-Engages Investor Relations Program
September 8, 2026  |  financialpost.comF
XORTX Re-Engages Investor Relations Program
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358245/0/en/xortx-re-engages-investor-relations-program.html
XORTX Slips 10% As Investor Relations Program Is Terminated And Postponed
August 28, 2026  |  rttnews.comhttps://www.rttnews.com/3686444/xortx-slips-10-as-investor-relations-program-is-terminated-and-postponed.aspx
XORTX Announces Termination and Postponement of Investor Relations Program
August 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/28/3352627/0/en/xortx-announces-termination-and-postponement-of-investor-relations-program.html
XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet
August 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xortx-therapeutics-files-august-form-6-k-highlighting-stronger-june-2026-balance-sheet?utm_source=marketbeat.com&utm_medium=referral
XORTX Therapeutics Inc.
August 11, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/xrtx/company-people
XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo
August 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xortx-therapeutics-announces-resignation-of-board-chairman-anthony-giovinazzo?utm_source=marketbeat.com&utm_medium=referral
XORTX Therapeutics Inc. annonce la démission d'Anthony Giovinazzo de son poste d'administrateur
August 2, 2026  |  zonebourse.comZ
XORTX Therapeutics Inc.: XORTX Announces Director Resignation
August 1, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69190082-xortx-therapeutics-inc-xortx-announces-director-resignation-399.htm
XORTX Announces Director Resignation
July 31, 2026  |  financialpost.comF
XORTX Announces Director Resignation
July 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3337071/0/en/xortx-announces-director-resignation.html
XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight
July 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xortx-therapeutics-adds-independent-director-to-strengthen-board-oversight?utm_source=marketbeat.com&utm_medium=referral
XORTX Appoints New Director
July 29, 2026  |  financialpost.comF
XORTX Appoints New Director
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335091/0/en/xortx-appoints-new-director.html
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
June 15, 2026  |  financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

PainReform stock logo

PainReform NASDAQ:PRFX

$1.01 +0.11 (+12.22%)
Closing price 09/16/2026 04:00 PM Eastern
Extended Trading
$1.04 +0.03 (+2.97%)
As of 09:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Redhill Biopharma stock logo

Redhill Biopharma NASDAQ:RDHL

$0.55 -0.03 (-4.36%)
Closing price 09/16/2026 04:00 PM Eastern
Extended Trading
$0.58 +0.03 (+6.00%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

60 Degrees Pharmaceuticals stock logo

60 Degrees Pharmaceuticals NASDAQ:SXTP

$0.92 +0.08 (+9.17%)
Closing price 09/16/2026 04:00 PM Eastern
Extended Trading
$0.91 -0.01 (-1.08%)
As of 08:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

XORTX Therapeutics stock logo

XORTX Therapeutics NASDAQ:XRTX

$1.78 -0.10 (-5.32%)
Closing price 09/16/2026 04:00 PM Eastern
Extended Trading
$1.74 -0.04 (-2.19%)
As of 09:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas